Galderma's constant-currency sales grew 26% in the third quarter, driven by strong volumes and positive mix effects. Results beat company-compiled consensus estimates by 6%, driving a 6% intraday increase in the stock price on Oct. 22.
Galderma’s sizable innovation pipeline should translate into accelerated revenue growth and EBITDA margin accretion over the midterm.
The agreement with Ipsen for the current neuromodulator portfolio features stepped royalties that have been weighing on margins and may limit the company in pursuing volume market share growth.
Metric | GALD | SNY | ABBV |
|---|---|---|---|
Price/Earnings (Normalized) | 62.33 | 12.53 | 33.44 |
Price/Book Value | 6.73 | 1.40 | — |
Price/Sales | 9.59 | 1.97 | 7.92 |
Price/Cash Flow | 47.54 | 8.40 | 22.25 |
Metric | GALD | SNY | ABBV |
|---|---|---|---|
Quick Ratio | 0.93 | 0.21 | 0.56 |
Current Ratio | 1.24 | 1.12 | 0.87 |
Interest Coverage | 6.84 | 9.10 | 5.20 |
Metric | GALD | SNY | ABBV |
|---|---|---|---|
Return on Assets (Normalized) | 7.31% | 8.44% | 16.61% |
Return on Equity (Normalized) | 12.07% | 15.62% | — |
Return on Invested Capital (Normalized) | 10.17% | 12.02% | 36.97% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|Yl@Qfqf | LOCK|KWF#> | $72B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|>X<CClf$ | LOCK|rWpc | $51B | |||
| Haleon PLC ADR HLN | LOCK|#f>DBq | LOCK|?J | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|^kXSl&#@ | LOCK|v<> | $34B | |||
| Viatris Inc VTRS | LOCK|p^n%$% | LOCK|rb | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|@&f | LOCK|Rq# | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|pkS>#s | LOCK|Gh | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|lzR$$Q | LOCK|MYF | $5B | |||
| Perrigo Co PLC PRGO | LOCK|QKB^%V | LOCK|Lt? | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|!RpYjc< | LOCK|#f$C@ | $2B |
United States